Related Experiment Video
Updated: Jun 27, 2026
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Single photon-emission computed tomography imaging in early Parkinson's disease
Angelo Antonini1, Ioannis U Isaias
1Parkinson Institute, Istituti Clinici di Perfezionamento, 20126 Milan, Italy. angelo3000@yahoo.com
Expert Review of Neurotherapeutics
|December 18, 2008
Summary
Early Parkinson's disease (PD) diagnosis is crucial for neuroprotection and can be achieved by recognizing nonmotor symptoms. Advanced imaging techniques, like single photon-emission computed tomography, show promise in identifying early PD and differentiating it from other conditions.
Area of Science:
- Neurology
- Medical Imaging
- Neuroscience
Background:
- Parkinson's disease (PD) diagnosis traditionally relies on motor symptoms, which manifest late.
- Early PD manifestations often include nonmotor symptoms affecting cognition, mood, olfaction, and sleep.
- Timely diagnosis is essential for initiating neuroprotective strategies.
Purpose of the Study:
- To review the role of single photon-emission computed tomography (SPECT) imaging in early Parkinson's disease detection.
- To explore SPECT's utility in differentiating PD from essential tremor and atypical parkinsonism.
- To discuss the application of imaging non-dopamine monoaminergic systems for assessing nonmotor features in PD.
Main Methods:
- Review of current literature on SPECT imaging in Parkinson's disease.
- Analysis of studies focusing on early diagnostic markers for PD.
- Discussion of imaging techniques for non-dopamine pathways.
Main Results:
- SPECT imaging can identify early pathological changes in PD before significant motor symptoms appear.
- SPECT aids in distinguishing PD from essential tremor and atypical parkinsonism.
- Imaging of non-dopamine systems correlates with nonmotor symptoms in PD.
Conclusions:
- SPECT imaging is a valuable tool for the early diagnosis and differential diagnosis of Parkinson's disease.
- Assessing nonmotor symptoms through advanced imaging is critical for comprehensive PD management.
- Further research into imaging biomarkers will enhance early detection and therapeutic interventions for PD.
Related Concept Videos
01:29Positron Emission Tomography
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...